am 251 has been researched along with Perceptual Disorders in 1 studies
AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.
Perceptual Disorders: Cognitive disorders characterized by an impaired ability to perceive the nature of objects or concepts through use of the sense organs. These include spatial neglect syndromes, where an individual does not attend to visual, auditory, or sensory stimuli presented from one side of the body.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, W | 1 |
| Jia, Y | 1 |
| Pham, DT | 1 |
| Palmer, LC | 1 |
| Jung, KM | 1 |
| Cox, CD | 1 |
| Rumbaugh, G | 1 |
| Piomelli, D | 1 |
| Gall, CM | 1 |
| Lynch, G | 1 |
1 other study available for am 251 and Perceptual Disorders
| Article | Year |
|---|---|
Atypical Endocannabinoid Signaling Initiates a New Form of Memory-Related Plasticity at a Cortical Input to Hippocampus.
Topics: Animals; Cerebral Cortex; Endocannabinoids; Enzyme Inhibitors; GABA Agents; Hippocampus; Lipid Metab | 2018 |